|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
InScape® ER/PR, Quantitative IHC without Interpretation [16711X]
Test Code16711
CPT Codes
88361 (x2)
Preferred Specimen
Formalin-fixed, paraffin-embedded tissue block
Other Acceptable Specimens
Minimum: 6 unstained, positively charged slides
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Unacceptable
Refrigerated: Indefinitely
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Received frozen
Methodology
Immunohistochemistry (IHC)
Setup Schedule
Set up: Mon-Fri; Report available: Next day
Reference Range
See Medical Report
Clinical Significance
Breast cancer is a heterogeneous disease and there is a continual drive to identify markers that will aid in predicting prognosis and response to therapy. Estrogen receptor (ER) is probably the most powerful predictive marker in breast cancer management, both in determining prognosis and in predicting response to hormone therapies. Progesterone receptor (PR) is an estrogen-regulated gene and its expression is therefore thought to indicate a functioning ER pathway, although its value is less well established.